Justin B. Klee Amylyx Pharmaceuticals, Inc. (AMLX) insider trading activity

Justin B. Klee is Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc.. Currently has a direct ownership of 3.38 Million shares of AMLX, which is worth approximately $42.9 Million. The most recent transaction as insider was on Jan 16, 2026, when has been sold 1,995 shares (Common Stock) at a price of $13.89 per share, resulting in proceeds of $27,710. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.38M

1.63% 3M change

6.38% 12M change

Total Value Held $42.9 Million

Justin B. Klee Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 16 2026	SELL Open market or private sale	$27,710 $13.89 p/Share	1,995 Reduced 0.06%	3,379,398 Common Stock
Jan 16 2026	BUY Exercise of conversion of derivative security	$21,551 $7.57 p/Share	2,847 Added 0.08%	3,381,393 Common Stock
Jan 15 2026	SELL Open market or private sale	$1,849,500 $13.58 p/Share	136,193 Reduced 3.87%	3,378,546 Common Stock
Jan 15 2026	BUY Exercise of conversion of derivative security	$1,492,448 $7.57 p/Share	197,153 Added 5.31%	3,514,739 Common Stock
Jan 06 2026	SELL Open market or private sale	$85,559 $11.09 p/Share	7,715 Reduced 0.23%	3,317,586 Common Stock
Sep 30 2025	SELL Open market or private sale	$440,332 $14.69 p/Share	29,975 Reduced 0.89%	3,325,301 Common Stock
Mar 31 2025	SELL Open market or private sale	$74,355 $3.46 p/Share	21,490 Reduced 0.64%	3,355,276 Common Stock

Mar 06 2025	BUY Grant, award, or other acquisition	-	180,118 Added 5.06%	3,376,766 Common Stock
Mar 03 2025	SELL Open market or private sale	$14,474 $3.15 p/Share	4,595 Reduced 0.14%	3,196,648 Common Stock
Feb 05 2025	BUY Exercise of conversion of derivative security	$57,006 $1.57 p/Share	36,310 Added 1.12%	3,201,243 Common Stock
Feb 03 2025	SELL Open market or private sale	$41,136 $3.47 p/Share	11,855 Reduced 0.37%	3,164,933 Common Stock
Jan 06 2025	SELL Open market or private sale	$30,182 $4.04 p/Share	7,471 Reduced 0.23%	3,176,788 Common Stock
Nov 04 2024	BUY Exercise of conversion of derivative security	$99,993 $1.57 p/Share	63,690 Added 1.96%	3,184,259 Common Stock
Sep 30 2024	SELL Open market or private sale	$59,484 $3.2 p/Share	18,589 Reduced 0.59%	3,120,569 Common Stock
Apr 16 2024	BUY Grant, award, or other acquisition	-	179,850 Added 5.42%	3,139,158 Common Stock
Mar 05 2024	SELL Open market or private sale	$77,448 $18.73 p/Share	4,135 Reduced 0.14%	2,959,308 Common Stock
Feb 26 2024	BUY Grant, award, or other acquisition	-	126,667 Added 4.1%	2,963,443 Common Stock
Jan 09 2024	SELL Open market or private sale	$95,383 $16.33 p/Share	5,841 Reduced 0.21%	2,836,776 Common Stock
Mar 16 2023	SELL Open market or private sale	$3,215,999 $32.16 p/Share	100,000 Reduced 3.46%	2,792,617 Common Stock
Mar 16 2023	BUY Grant, award, or other acquisition	-	50,000 Added 1.73%	2,842,617 Common Stock
Jan 06 2023	BUY Open market or private sale	$217,473 $36.44 p/Share	5,968 Added 0.21%	2,892,617 Common Stock
May 05 2022	BUY Exercise of conversion of derivative security	$123,772 $0.37 p/Share	334,520 Added 10.35%	2,898,585 Common Stock
Jan 06 2022	BUY Conversion of derivative security	-	4,870 Added 0.2%	2,489,065 Common Stock
Jan 06 2022	BUY Grant, award, or other acquisition	-	75,000 Added 2.84%	2,564,065 Common Stock

JBK

Justin B. Klee

Co-Chief Executive Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMLX shares.

Notify only if

Value

Insider Trading

Get notified when an Amylyx Pharmaceuticals, Inc. insider buys or sells AMLX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Amylyx Pharmaceuticals, Inc.

Track Activities on AMLX

Account